The first quarter results for the Medical Device sector showed slowing deal volume. A handful of big deals meant spending showed a slight gain.
Becton, Dickinson’s $24 billion deal for C.R. Bard helps it expand into markets outside the United States, and to treat diseases beyond diabetes.
Cardinal Health, Inc. announced its $6.1 billion acquisition of three Medtronic businesses on the same day it disappointed shareholders with its 2017 guidance update.
Mergers and acquisitions in the Rehabilitation sector continued the climb that began in 2014, with a 21% increase in deal volume since 2015.
Now that managed care giants are blocked from acquiring each other, they may look outside the sector for growth.
The Pharmaceutical sector hasn’t wasted any time getting busy in the New Year. As of January 18, 2017, 10 pharma deals have been announced, with disclosed prices totaling $7.18 billion. Of course, the annual JP Morgan Healthcare Summit, held this year from January 9 to January 13, helped to boost the announcements. The largest deal so […]
Mergers and acquisitions in the Physician Medical Group sector hit a record 119 transactions in 2016, up 19% over 2015’s previous record of 100 announced transactions. Consolidation was a big theme, as some of the top publicly traded companies either merged or were taken private.
Medical Devices is finishing the year on a high note. In fact, as of December 29, 2016, deal volume reached 113 transactions, equal to 2015’s total. Deal value topped off at $61.3 billion, a 111% increase from last year’s total of $29.1 billion.
Behavioral health care has been a hot sector for investors in recent years. After slumping to just eight announced transactions in 2010, deal volume soared steadily to 40 transactions in 2015. As of this writing, the sector has recorded 40 transactions in 2016, with two weeks left in the year.
On November 10, 2016, Bristol-Meyers Squibb (NYSE: BMY) purchased the exclusive worldwide rights to develop and commercialize Nitto Denko Corporation’s (TYO: 6988) investigational siRNA, which includes Nitto’s lead asset ND-L02-s0201. Nitto’s lead asset ND-L02-s0201 is currently in a five-week open-label Phase 1b study in patients with advanced fibrosis (F3-F4c) due to non-alcoholic steatohepatitis (NASH) or […]